Clinical Trial

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Study acronym: ENABLE
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
Protocol Amendment History 5 changes
notable Trial sites expanded: 85 -> 88 locations 2026-05-30
notable Enrollment increased: 500 -> 2000 participants 2026-05-16
notable Primary completion pushed: 2027-07-01 -> 2032-04-01 2026-05-16
minor Completion pushed: 2027-07-01 -> 2032-04-01 2026-05-16
notable Trial sites expanded: 80 -> 85 locations 2026-04-08
Trial Details
NCT Number NCT06433752
Lead Sponsor TG Therapeutics, Inc.
Conditions Relapsing Multiple Sclerosis, Multiple Sclerosis
Enrollment 2,000 participants
Start Date 2024-07-22
Primary Completion 2032-04-01 (estimated)
Study Completion 2032-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-20